Key changes in Group Dynamics

– Changes in the leadership team
– New financing from GEM
– Conclusion
– Valuation

Advancing the development of atexakin alfa

–  Strategic collaboration agreement with PX’Therapeutics
–  Strategic collaboration agreement with FirstString
–  Conclusion
–  Valuation

Addressing diabetes and respiratory disease

– Attractive potential in underserved markets
– Commercial exclusivity through proprietary patents and orphan drug designations
– Strengthening the pipeline through acquisitions
– Valuation